Anti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 Patients

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 1, 2011, Pages 61-70

  Arida, Aikaterini ^a   Fragiadaki, Kalliopi ^a   Giavri, Eirini ^a   Sfikakis, Petros P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adalimumab; Anti TNF agents; Behcet's disease; Etanercept; Gastrointestinal; Infliximab; Nervous system; Uveitis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ADD ON THERAPY; ANGIONEUROTIC EDEMA; ARTHRITIS; ARTICLE; ATOPIC DERMATITIS; BACTERIAL ENDOCARDITIS; BEHCET DISEASE; CATARACT; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL SINUS THROMBOSIS; COLITIS; CRYPTOCOCCAL MENINGITIS; CYTOMEGALOVIRUS COLITIS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; EYE DISEASE; FATIGUE; FLUSHING; GASTROINTESTINAL DISEASE; GENITAL ULCER; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE ERYTHEMA; INTRAOCULAR PRESSURE; LEGIONNAIRE DISEASE; LIVER VEIN THROMBOSIS; MOUTH ULCER; NONHODGKIN LYMPHOMA; OSTEOMALACIA; PERIANAL ABSCESS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PULMONARY ARTERY ANEURYSM; PYOMYOSITIS; REMISSION; RESPIRATORY TRACT INFECTION; RETINA MACULA CYSTOID EDEMA; SCLEROMALACIA; SIDE EFFECT; SKIN DISEASE; SUBRETINAL NEOVASCULARIZATION; THORAX PAIN; THROMBOPHLEBITIS; TUBERCULOSIS; URTICARIA; UVEITIS; VITREOUS HEMORRHAGE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BEHCET SYNDROME; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MEDLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959599276     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.09.002     Document Type: Article

References (98)

1. Sakane T., Takeno M., Suzuki N., Inaba G. Behçet's disease. N Engl J Med 1999, 341:1284-1291.
2. Zouboulis C.C. Epidemiology of Adamantiades-Behçet's disease. Ann Med Interne (Paris) 1999, 150:488-498.
3. Yazici H., Seyahi E., Yurdakul S. Behcet's syndrome is not so rare: why do we need to know?. Arthritis Rheum 2008, 58:3640-3643.
4. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990, 335:1078-1080.
5. Krause I., Uziel Y., Guedj D., Mukamel M., Molad Y., Amit M., et al. Mode of presentation and multisystem involvement in Behçet's disease: the influence of sex and age of disease onset. J Rheumatol 1998, 25:1566-1569.
6. Kural-Seyahi E., Fresko I., Seyahi N., Ozyazgan Y., Mat C., Hamuryudan V., et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003, 82:60-76.
7. Yazici H., Fresko I., Yurdakul S. Behcet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007, 3:148-155.
8. Kotter I., Hamuryudan V., Ozturk Z.E., Yazici H. Interferon therapy in rheumatic diseases: state of the art 2010. Curr Opin Rheumatol 2010, 22:278-283.
9. Sfikakis P.P. Behcet's disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis 2002, 61(Suppl 2):51-53.
10. Turan B., Gallati H., Erdi H., Gürler A., Michel B.A., Villiger P.M. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997, 24:128-132.
11. Evereklioglu C., Er H., Türköz Y., Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002, 11:87-93.
12. Santos Lacomba M., Marcos Martín C., Gallardo Galera J.M., Gómez Vidal M.A., Collantes Estévez E., Ramírez Chamond R., et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001, 33:251-255.
13. Aeberli D., Oertle S., Mauron H., Reichenbach S., Jordi B., Villiger P.M. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002, 132:414-422.
14. Joseph A., Raj D., Dua H.S., Powell P.T., Lanyon P.C., Powell R.J. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003, 110:1449-1453.
15. Falappone P.C., Iannone F., Scioscia C., Grattagliano V., Covelli M., Lapadula G. The treatment of recurrent uveitis with TNF-alpha inhibitors. Reumatismo 2004, 56:185-189.
16. Markomichelakis N.N., Theodossiadis P.G., Pantelia E., Papaefthimiou S., Theodossiadis G.P., Sfikakis P.P. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004, 138:648-650.
17. Wechsler B., Sablé-Fourtassou R., Bodaghi B., Huong D.L., Cassoux N., Badelon I., et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 2004, 22(4 Suppl 34):S14-S16.
18. Lanthier N., Parc C., Scavennec R., Dhte R., Brézin A.P., Guillevi L. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients. Presse Med 2005, 34:916-918.
19. Cobo-Ibáñez T., Muñoz-Fernández S., Hidalgo-Barrero V., Martín-Mola E. Medium-long term treatment with infliximab and methotrexate in posterior and/or chronic uveitis refractory to conventional treatment. Med Clin (Barc) 2006, 126:34-35.
20. Saurenmann R.K., Levin A.V., Rose J.B., Parker S., Rabinovitch T., Tyrrell P.N., et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006, 45:982-989.
21. Mushtaq B., Saeed T., Situnayake R.D., Murray P.I. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) 2007, 21:824-825.
22. Seyahi E., Hamuryudan V., Hatemi G., Melikoglu M., Celik S., Fresko I., et al. Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet's syndrome. Rheumatology (Oxford) 2007, 46:1213-1214.
23. Suhler E.B., Smith J.R., Giles T.R., Lauer A.K., Wertheim M.S., Kurz D.E., et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009, 127:819-822.
24. Cantarini L., Tinazzi I., Caramaschi P., Bellisai F., Brogna A., Galeazzi M. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. Int J Immunopathol Pharmacol 2009, 22:551-555.
25. Callejas-Rubio J.L., Sánchez-Cano D., Serrano J.L., Ortego-Centeno N. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008, 24:613-614. author reply 614.
26. Diaz-Llopis M., García-Delpech S., Salom D., Udaondo P., Hernández-Garfella M., Bosch-Morell F., et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008, 24:351-361.
27. Bodaghi B., Bui Quoc E., Wechsler B., Tran T.H., Cassoux N., Le Thi Huong D., et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 2005, 64:962-964.
28. Merino G., Varas G., Díaz G., Gutiérrez M., Massardo L., Pacheco D., et al. Effectiveness of infliximab in patients with Behçet syndrome and severe uveoretinitis. Report of five cases. Rev Med Chil 2006, 134:875-882.
29. van Laar J.A., Missotten T., van Daele P.L., Jamnitski A., Baarsma G.S., van Hagen P.M. Adalimumab: a new modality for Behçet's disease?. Ann Rheum Dis 2007, 66:565-566.
30. Pipitone N., Olivieri I., Padula A., D'Angelo S., Nigro A., Zuccoli G., et al. Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum 2008, 59:285-290.
31. Naganuma M., Sakuraba A., Hisamatsu T., Ochiai H., Hasegawa H., Ogata H., et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 2008, 14:1259-1264.
32. Tabbara K.F., Al-Hemidan A.I. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol 2008, 146:845-850.
33. Lopez-Gonzalez R., Loza E., Jover J.A., Benitez Del Castillo J.M., Mendez R., Hernandez-Garcia C., et al. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Scand J Rheumatol 2009, 38:58-62.
34. Yamada Y., Sugita S., Tanaka H., Kamoi K., Kawaguchi T., Mochizuki M. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behcet's disease. Br J Ophthalmol 2010, 94(3):284-288.
35. Callejas-Rubio J.L., Sánchez-Cano D., Ríos-Férnandez R., Ortego-Centeno N. Treatment of Behçet's disease with adalimumab. Med Clin (Barc) 2008, 131:438-439.
36. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., Kaklamanis P., Markomichelakis N.N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001, 358:295-296.
37. Sfikakis P.P., Kaklamanis P.H., Elezoglou A., Katsilambros N., Theodossiadis P.G., Papaefthimiou S., et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004, 140:404-406.
38. Ohno S., Nakamura S., Hori S., Shimakawa M., Kawashima H., Mochizuki M., et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004, 31:1362-1368.
39. Benitez-del-Castillo J.M., Martinez-de-la-Casa J.M., Pato-Cour E., Méndez-Fernández R., López-Abad C., Matilla M., et al. Long-term treatment of refractory posterior uveitis with anti-TNF-alpha (infliximab). Eye 2005, 19:841-845.
40. Lindstedt E.W., Baarsma G.S., Kuijpers R.W., van Hagen P.M. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005, 89:533-536.
41. Arayssi T., Hamra R., Homeidan F., Uthman I., Awwad S.T., Mroue K. The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis. Clin Exp Rheumatol 2005, 23:427.
42. Tugal-Tutkun I., Mudun A., Urgancioglu M., Kamali S., Kasapoglu E., Inanc M., et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005, 52:2478-2484.
43. Abu El-Asrar A.M., Abboud E.B., Aldibhi H., Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol 2005, 26:83-92.
44. Niccoli L., Nannini C., Benucci M., Chindamo D., Cassarà E., Salvarani C., et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007, 46:1161-1164.
45. Accorinti M., Pirraglia M.P., Paroli M.P., Priori R., Conti F., Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 2007, 51:191-196.
46. Tognon S., Graziani G., Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Ann NY Acad Sci 2007, 1110:474-484.
47. Al-Rayes H., Al-Swailem R., Al-Balawi M., Al-Dohayan N., Al-Zaidi S., Tariq M. Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial. Rheumatol Int 2008, 29:53-57.
48. Kikuchi H., Aramaki K., Hirohata S. Effect of infliximab in progressive neuro-Behçet's syndrome. J Neurol Sci 2008, 272:99-105.
49. Iwata S., Saito K., Yamaoka K., Tsujimura S., Nawata M., Suzuki K., et al. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Rheumatology (Oxford) 2009, 48:1012-1013.
50. Giardina A., Ferrante A., Ciccia F., Vadalà M., Giardina E., Triolo G. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Rheumatol Int 2009, [Epub ahead of print].
51. Tanaka H., Sugita S., Yamada Y., Kawaguchi T., Iwanaga Y., Kamoi K., et al. Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease. Nippon Ganka Gakkai Zasshi 2010, 114:87-95.
52. Melikoglu M., Fresko I., Mat C., Ozyazgan Y., Gogus F., Yurdakul S., et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005, 32:98-105.
53. Andonopoulos A.P., Meimaris N., Daoussis D., Bounas A., Yiannopoulos G. Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behçet's disease. Clin Exp Rheumatol 2003, 21(4 Suppl 30):S57-S58.
54. Sakellariou G., Berberidis C., Vounotrypidis P. A case of Behcet's disease with scleromalakia perforans. Rheumatology 2005, 44:258-260.
55. Giansanti F., Barbela M.L., Virgili G., et al. Infliximab for the threatment of posterior uveitis with retinal neovascularization in Behcet's disease. Eur J Ophthalmol 2004, 14:445-448.
56. Evereklioglu C., Borlu M. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha. Br J Ophthalmol 2008, 92:1034. 1148-9.
57. Sari I., Birlik M., Gonen C., Akar S., Gurel D., Onen F., et al. Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008, 14:2912-2914.
58. Mancini G., Erario L., Gianfreda R., Oliva A., Massetti A.P., Mastroianni C.M., et al. Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment. Clin Microbiol Infect 2007, 13:1036-1037.
59. Takase K., Ohno S., Ideguchi H., Uchio E., Takeno M., Ishigatsubo Y. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 2009, [Epub ahead of print].
60. Belzunegui J., López L., Paniagua I., Intxausti J.J., Maíz O. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease. Clin Exp Rheumatol 2008, 26(4 Suppl 50):S133-S134.
61. Hassard P.V., Binder S.W., Nelson V., Vasiliauskas E.A. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001, 120:995-999.
62. Travis S.P., Czajkowski M., McGovern D.P., Watson R.G., Bell A.L. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001, 49:725-728.
63. Kram M.T., May L.D., Goodman S., Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003, 46:118-121.
64. Ju J.H., Kwok S.K., Seo S.H., Yoon C.H., Kim H.Y., Park S.H. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol 2007, 26:1383-1385.
65. Lee J.H., Kim T.N., Choi S.T., Jang B.I., Shin K.C., Lee S.B., et al. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007, 22:24-27.
66. Aikawa N.E., Gonçalves C., Silva C.A., Gonçalves C., Bonfá E., de Carvalho J.F. Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Behçet's disease. Rheumatol Int 2009 Dec, [Epub ahead of print].
67. Alty J.E., Monaghan T.M., Bamford J.M. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNF-alpha blockade. Clin Neurol Neurosurg 2007, 109:279-281.
68. Baki K., Villiger P.M., Jenni D., Meyer T., Beer J.H. Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis 2006, 65:1531-1532.
69. Endo L.M., Rowe S.M., Romp R.L., Buckmaster M.A., Atkinson T.P. Pulmonary aneurysms and intracardiac thrombi due to Behçet's disease in an African-American adolescent with oculocutaneous albinism. Clin Rheumatol 2007, 26:1537-1539.
70. Triolo G., Vadalà M., Accardo-Palumbo A., Ferrante A., Ciccia F., Giardina E., et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis 2002, 61:560-561.
71. Lee S.W., Lee S.Y., Kim K.N., Jung J.K., Chung W.T. Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report. Clin Rheumatol 2010, 29:91-93.
72. Yee A.M., Pochapin M.B. Treatment of complicated sarcoidosis with Infliximab anti-tumour necrosis factor-alpha therapy. Ann Intern Med 2001, 135:27-31.
73. Puli S.R., Benage D.D. Retinal vein thrombosis after Infliximab (Remicade) treatment for Crohn's disease. Am J Gastroenterol 2003, 98:939-940.
74. Goossens P.H., Verburg R.J., Breedveld F.C. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 2001, 60:637.
75. Robertson L.P., Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford) 2001, 40:473-474.
76. Saulsbury F.T., Mann J.A. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum 2003, 49:599-600.
77. Haugeberg G., Velken M., Johnsen V. Successful treatment of genital ulcers with infliximab in Behcet's disease. Ann Rheum Dis 2004, 63:744-745.
78. Connolly M., Armstrong J.S., Buckley D.A. Infliximab treatment for severe orogenital ulceration in Behçet's disease. Br J Dermatol 2005, 153:1073-1075.
79. Almoznino G., Ben-Chetrit E. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature. Clin Exp Rheumatol 2007, 25(4 Suppl 45):S99-S102.
80. Byeon J.S., Choi E.K., Heo N.Y., Hong S.C., Myung S.J., Yang S.K., et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum 2007, 50:672-676.
81. Mussack T., Landauer N., Ladurner R., Schiemann U., Goetzberger M., Burchardi C., et al. Successful treatment of cervical esophageal perforation in Behcet's disease with drainage operation and infliximab. Am J Gastroenterol 2003, 98:703-704.
82. Licata G., Pinto A., Tuttolomondo A., Banco A., Ciccia F., Ferrante A., et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis 2003, 62:280-281.
83. Ribi C., Sztajzel R., Delavelle J., Chizzolini C. Efficacy of TNF α blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry 2005, 76:1733-1735.
84. Sarwar H., McGrath H., Espinoza L.R. Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol 2005, 32:181-183.
85. Fujikawa K., Aratake K., Kawakami A., Aramaki T., Iwanaga N., Izumi Y., et al. Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 2007, 66:136-137.
86. Madanat W.Y., Madanat A.Y., et al. Worsening of osteomalacia in a patient successfully treated for neuro-Behçet's disease with infliximab. Clin Exp Rheumatol 2008, 26(4 Suppl 50):S128-S129.
87. Sfikakis P.P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010, 11:180-210.
88. Borhani Haghighi A., Safari A. Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report. Clin Neurol Neurosurg 2008, 110:315-316.
89. Kluger N., Poirier P., Guilpain P., Baixench M.T., Cohen P., Paugam A. Cryptococcal meningitis in a patient treated with infliximab and mycophenolate mofetil for Behcet's disease. Int J Infect Dis 2009, 13:e325.
90. Elezoglou A., Kafasi N., Kaklamanis P.H., Theodossiadis P.G., Kapsimali V., Choremi E., et al. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. Clin Exp Rheumatol 2007, 25:S65-S69.
91. Sfikakis P.P., Iliopoulos A., Elezoglou A., Kittas C., Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005, 52:2513-2518.
92. Sfikakis P.P., Markomichelakis N., Alpsoy E., Assaad-Khalil S., Bodaghi B., Gul A., et al. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 2007, 46:736-741.
93. Hatemi G., Silman A., Bang Y., Bodaghi B., Chamberlain A., Dougados M., et al. EULAR recommendations for the management of Behcet's disease. Ann Rheum Dis 2008, 67:1656-1662.
94. Kötter I., Günaydin I., Zierhut M., Stübiger N. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum 2004, 33:320-335.
95. Markomichelakis N., Delicha E., Masselos S., Fragiadaki K., Kaklamanis P., Sfikakis P.P. Infliximab versus corticosteroids for sight-threatening panuveitis relapse in Behçet's disease: a comparative 4-week study. Rheumatology (Oxford) 2010, (in press).
96. Morris D.S., Gavin M.P., Sturrock R.D. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease. Adv Exp Med Biol 2003, 528:557-559.
97. Yücel A.E., Kart-Köseoglu H., Akova Y.A., Demirhan B., Boyacioglu S. Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease. Rheumatology (Oxford) 2004, 43:394-396.
98. Sànchez-Cano D., Callejas-Rubio J.L., Ortego-Centeno N., Ruiz-Villaverde R. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab. Clin Exp Rheumatol 2006, 24(5 Suppl 42):S128. Erratum in: Clin Exp Rheumatol 2007;25:507-8.